The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
Recruiting now · Not applicable
Conditions studied: Surgery
In brief
The study is enrolling adults who are scheduled for either inpatient or outpatient elective surgical procedures at The University of Chicago. At pre-operative visits, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk. Genotyping results will be delivered to participating providers as patient-specific drug-gene clinical decision support summaries using a secured Web portal, the Genomic Prescribing System (GPS). Participating anesthesiologists and critical care and pain management physicians and associated providers from the Department of Anesthesia and Critical Care at the University of Chicago will be invited to receive results for their participating patients. There will be an initial 6- month "run-in" period of the study comprised of approximately 100 enrolled adults in which all patients will have pharmacogenomic results made available to providers. The run-in period will allow for process refinement and GPS delivery to be examined and optimized prior to the randomized phase After the initial run-in period, patients will be randomized to one of two arms - in the pharmacogenomic arm, providers will have access to GPS and pharmacogenomic information, whereas in the control arm, providers will not have access to GPS and patient-specific pharmacogenomic information (current standard of care).
Key facts
- Study ID
- NCT03729180
- Run by
- University of Chicago
- People needed
- 1900
- Starts
- 2019-01-22
- Expected to finish
- 2027-08-22
- Last updated by the study team
- 2026-04-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Adult patients who have planned elective surgical procedures at the University of Chicago
- Must be aged 18 years or older
You may not qualify if…
- Patients who have undergone, or are being actively considered for, liver or kidney transplantation
- Patients with known active or prior leukemia.
- Inability to understand and give informed consent to participate.
Where it is running
- University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.